Multi-kinase inhibitors (that inhibit aurora kinases and critical signaling molecules in AML, e.g., FLT3, JAK2), e.g., MK-0457, KW-2449, AT9283. This evidence concerns the gene JAK2 and acute myeloid leukemia.